Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06838338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

StatusActive, Not Recruiting
PhasePhase 1
SponsorJian Li
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 8, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Phase 1v2 Show 7 more changesShow less
    • Start date: Aug 29, 2024 to Mar 20, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 4
    • Primary completion date: Jun 2026 to Mar 2026
    • Study completion date: Jun 2026 to Aug 2026
    • Study description revised
    • Study title expanded, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jian Li
3 trials monitored
See all monitored trials
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard chemotherapy and bevacizumab in advanced colorectal cancer failed to standard therapy in Chinese population.
Trial Details
NCT Number NCT06838338
Lead Sponsor Jian Li
Conditions
(from sponsor)		 Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov